Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

he time of their acquisition.

(d) Intangible assets capitalised

Up-front and milestone payments in respect of in-licensed technology of US$147.8 million (2006: US$80.5 million) have been capitalised under IFRS: these payments have been expensed as research and development costs as incurred under US GAAP.

(e) Effective settlement of the pre-existing relationship with New River

A non-cash charge under IFRS of US$100.0 million arose on effective settlement of the Group's pre-existing relationship with New River, in respect of the write-off of up-front and milestone payments capitalised under IFRS as intangible assets; no loss was recorded under US GAAP as these payments had been expensed as a research and development cost as incurred.

(f) Finance costs in respect of convertible bonds

Finance costs recognised in respect of the US$1,100.0 million 2.75% convertible bonds due 2014 are US$21.9 million (2006: US$nil) higher under IFRS compared to US GAAP.

Under both US GAAP and IFRS finance costs include the stated coupon on the bonds, together with amortisation of the direct costs of issue. However, under IFRS, finance costs also include amortisation of the discount arising from separately accounting for the equity conversion feature at inception; this equity conversion feature is not separately accounted for under US GAAP. Finance costs are higher under IFRS as compared to US GAAP as a result of the amortisation of this discount.

(g) Other differences

Other differences include goodwill allocated to the gain on disposal of product rights; adjustments to goodwill relating to prior years acquisitions; the amortisation of intangible assets capitalised under IFRS and not US GAAP; accruals for payroll taxes on share options; and share based payment charges.

Consolidated income statement

Year to December 31, Notes 2007 2006


'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014 Spartan Bioscience announced today that ... System . It detects CYP2C19 genetic mutations in less ... The Spartan RX CYP2C19 System is the first near-patient ... in Canada. Due to the system’s ease of use, ... by healthcare professionals such as doctors, nurses, pharmacists, and ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... that devastated a wide swath of Colorado last year ... and other infrastructure had been upgraded or modernized, according ... Denver. , "People need to understand the importance and ... of structural engineering at the CU Denver College of ... "There is an assumption that a bridge will stand ...
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... Cell Assurance, Inc. (SCLZ.PK) announced today that it has ... 10 pursuant to Section 12(g) of the Securities Exchange Act ... of December 31, 2009 and 2010 and for the years ... the Company will become an SEC reporting company and will ...
... Healthcare (NYSE: SI ) has appointed Gregory ... Healthcare in the U.S.A., effective June 1.  Sorensen succeeds ... Sorensen will also oversee the Canadian activities of Siemens ... Sorensen will be responsible for leading the marketing, ...
... Rules-Based Medicine, Inc. a leading provider of multiplexed protein ... Pasteur research project Milieu Interieur (the environment ... government.  The project will rely on RBM,s TruCulture®, an ... cellular interactions, to more accurately describe the complexities of ...
Cached Biology Technology:Gregory Sorensen to Head Siemens Healthcare U.S. and Canada Organizations 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 2Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 3Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research 4
(Date:10/29/2014)... 27, 2014 — Cambridge, MA and Hebei, China — ... complete, high quality sequencing of the Jujube genome. Jujube ... family, and the Jujube genome is particularly difficult to ... complicating factors. It is the first time that a ... This study has been recently published in ...
(Date:10/29/2014)... on a large cohort of kidney cancer patients in ... disease -- and reveals an apparent link between exposure ... in Romania. , The research, by an international team ... Quebec Innovation Centre in Montreal, underscores the importance of ... compound, found in plants of the Aristolochia genus, also ...
(Date:10/28/2014)... Institute of Health (NIH) announced awards to expand ... the National Center for Advancing Translational Sciences (ORDR-NCATS) ... Through the network, physician scientists at 22 consortia ... advance clinical research and investigate new treatments for ... possible by $29 million in fiscal 2014 funding ...
Breaking Biology News(10 mins):BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... is available in German . , It is ... fate of individual cells during the early development of organisms. ... of molecular biologists led by Pia Aanstad of the University ... for the interpretation of the concentration of the signaling molecule ...
... Global Crop Diversity Trust announced today numerous new grant ... seed samples maintained in 1,500 crop genebanks around the ... protect food production from the ravages of climate change. ... innovative projects, including a search in Southeast Asia and ...
... experimental vaccine applied the surface of the skin appears ... Scientists from the Research Institute at Nationwide Children,s Hospital ... 109th General Meeting of the American Society for Microbiology ... show that transcutaneous immunization is an effective way to ...
Cached Biology News:Why the thumb of the right hand is on the left hand side 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 2Hunt for 'climate-ready' crops accelerates as organizations search seed collections worldwide 3Preventing ear infections in the future: Delivering vaccine through the skin 2
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: